Viridian Therapeutics, Inc.\DE Quarterly Deferred Tax Assets, Valuation Allowance in USD from Q4 2014 to Q4 2023

Taxonomy & unit
us-gaap: USD
Description
Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.
Summary
Viridian Therapeutics, Inc.\DE quarterly Deferred Tax Assets, Valuation Allowance history and growth rate from Q4 2014 to Q4 2023.
  • Viridian Therapeutics, Inc.\DE Deferred Tax Assets, Valuation Allowance for the quarter ending December 31, 2023 was $156M, a 79.8% increase year-over-year.
Deferred Tax Assets, Valuation Allowance, Quarterly (USD)
Deferred Tax Assets, Valuation Allowance, YoY Quarterly Growth (%)
Period Value YoY Chg Change % Date Report Filed
Q4 2023 $156M +$69.1M +79.8% Dec 31, 2023 10-K 2024-02-27
Q4 2022 $86.6M +$33.2M +62.1% Dec 31, 2022 10-K 2024-02-27
Q4 2021 $53.4M +$24.4M +83.8% Dec 31, 2021 10-K 2024-02-27
Q4 2020 $29.1M -$17.2M -37.1% Dec 31, 2020 10-K 2022-03-11
Q4 2019 $46.2M +$13.1M +39.5% Dec 31, 2019 10-K 2021-03-26
Q4 2018 $33.1M +$10.6M +47.2% Dec 31, 2018 10-K 2020-03-13
Q4 2017 $22.5M -$3.83M -14.6% Dec 31, 2017 10-K 2019-03-14
Q4 2016 $26.3M +$21.6M +461% Dec 31, 2016 10-K 2018-03-15
Q4 2015 $4.7M +$3.5M +293% Dec 31, 2015 10-K 2017-03-24
Q4 2014 $1.2M Dec 31, 2014 10-K 2016-03-21
* An asterisk sign (*) next to the value indicates that the value is likely invalid.